

Gilbert Spizzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9154381/publications.pdf>

Version: 2024-02-01

58
papers

3,541
citations

293460

24
h-index

175968

55
g-index

59
all docs

59
docs citations

59
times ranked

6455
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfusion-associated circulatory overload in gastroenterology. <i>Blood Transfusion</i> , 2021, 19, 197-204.	0.3	5
2	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	2.0	26
3	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
4	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
5	Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 23.	0.6	5
6	Curcumin: New Insights into an Ancient Ingredient against Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1808.	1.8	109
7	Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 447-453.	1.9	17
8	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3588-3588.	0.8	7
9	Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4085-4085.	0.8	12
10	Association of <i>BRCA</i> -mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4133-4133.	0.8	12
11	Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. <i>Stem Cells Translational Medicine</i> , 2018, 7, 495-501.	1.6	59
12	What's new in small cell lung cancer "extensive disease"? An overview on advances of systemic treatment in 2016. <i>Future Oncology</i> , 2017, 13, 1427-1435.	1.1	4
13	Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 657-663.	2.3	17
14	Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation. <i>Prostate International</i> , 2016, 4, 54-55.	1.2	0
15	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. <i>Neuroendocrinology</i> , 2016, 103, 321-334.	1.2	19
16	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	1.1	8
17	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. <i>Genes and Cancer</i> , 2016, 7, 301-308.	0.6	15
18	Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. <i>BMC Cancer</i> , 2015, 15, 372.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 449-460.	1.1	24
20	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	0.8	6
21	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16017-e16017.	0.8	1
22	Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. <i>Oncotarget</i> , 2015, 6, 25017-25023.	0.8	14
23	Expression of EpCAM ^{MF} and EpCAM ^{MT} variants in human carcinomas. <i>Journal of Clinical Pathology</i> , 2014, 67, 408-414.	1.0	43
24	Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. <i>Future Oncology</i> , 2014, 10, 985-993.	1.1	23
25	Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. <i>Histopathology</i> , 2014, 64, 683-692.	1.6	34
26	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014, 32, 92-92.	0.8	2
27	Looking to possible predictive factors of primary resistance to abiraterone acetate (AA) and enzalutamide (ENZ) in pretreated patients (pts) with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 248-248.	0.8	1
28	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2014, 32, 214-214.	0.8	0
29	Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15173-e15173.	0.8	0
30	Potential value of rapid prostate-specific antigen (PSA) decline, in identifying primary resistance (PRes) to abiraterone acetate (AA) and enzalutamide (ENZ), in pre-treated castration resistant prostate cancer (CRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16044-e16044.	0.8	0
31	EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. <i>Molecular Cancer</i> , 2013, 12, 56.	7.9	31
32	Low Expression of Junctional Adhesion Molecule A Is Associated with Metastasis and Poor Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 4330-4336.	0.7	38
33	Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. <i>BMC Cancer</i> , 2012, 12, 501.	1.1	91
34	Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	23
35	Effects of EpCAM overexpression on human breast cancer cell lines. <i>BMC Cancer</i> , 2011, 11, 45.	1.1	60
36	Interlaboratory Comparison of K-ras Testing by Real-time PCR and RFLP in Colorectal Cancer Samples. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 90-93.	2.1	4

#	ARTICLE	IF	CITATIONS
37	EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. <i>Journal of Clinical Pathology</i> , 2011, 64, 415-420.	1.0	214
38	Clinical Aspects, Diagnostic Challenges and Management of Patients with Neuroendocrine Tumors (NETs). <i>Onkologie</i> , 2011, 34, 139-146.	1.1	4
39	Bortezomib for the treatment of refractory Type β cryoglobulinaemia. <i>British Journal of Haematology</i> , 2010, 150, 235-237.	1.2	15
40	Prognostic significance of 14-3-3 β expression in oral squamous cell carcinoma (OSCC). <i>Oral Oncology</i> , 2009, 45, 127-134.	0.8	10
41	Hodgkin lymphoma in Tyrol—a population-based study. <i>Annals of Hematology</i> , 2009, 88, 449-456.	0.8	5
42	TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. <i>Modern Pathology</i> , 2008, 21, 186-191.	2.9	141
43	EpCAM expression in squamous cell carcinoma of the oral cavity: Frequency and relationship to clinicopathologic features. <i>Oral Oncology</i> , 2008, 44, 72-77.	0.8	22
44	Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. <i>Cancer Letters</i> , 2007, 246, 253-261.	3.2	30
45	Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. <i>Respiratory Research</i> , 2007, 8, 50.	1.4	88
46	STAT1 activation in squamous cell cancer of the oral cavity. <i>Cancer</i> , 2007, 110, 326-333.	2.0	35
47	Epigenetic stem cell signature in cancer. <i>Nature Genetics</i> , 2007, 39, 157-158.	9.4	1,023
48	High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. <i>Oral Oncology</i> , 2007, 43, 193-198.	0.8	115
49	EpCAM Overexpression in Thyroid Carcinomas. <i>Journal of Immunotherapy</i> , 2006, 29, 569-573.	1.2	26
50	Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 483-488.	0.6	177
51	Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. <i>British Journal of Haematology</i> , 2005, 129, 199-205.	1.2	66
52	14-3-3 β Expression Is an Independent Prognostic Parameter for Poor Survival in Colorectal Carcinoma Patients. <i>Clinical Cancer Research</i> , 2005, 11, 3274-3279.	3.2	87
53	Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival. <i>Clinical Cancer Research</i> , 2004, 10, 3131-3136.	3.2	130
54	High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 207-213.	1.1	211

#	ARTICLE	IF	CITATIONS
55	Edrecolomab in the adjuvant treatment of colorectal carcinoma. Lancet, The, 2003, 361, 83.	6.3	5
56	In vivo Release of Vascular Endothelial Growth Factor from Colorectal Carcinomas. Oncology, 2002, 62, 313-317.	0.9	15
57	Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. International Journal of Cancer, 2002, 98, 883-888.	2.3	89
58	Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet, The, 2000, 356, 1981-1982.	6.3	228